Point of Care Diagnostics Market worth $31.46 billion by 2031 | MarketsandMarkets™

MarketsandMarkets projects the global point-of-care (POC) diagnostics market will rise from about $20.63B in 2026 to $31.46B by 2031 (8.8% CAGR). Growth is attributed to higher burdens of diabetes, infectious and respiratory diseases, and chronic kidney disorders, driving demand for rapid, decentralized testing (e.g., glucose monitoring, rapid infectious tests, cardiac biomarkers). The report highlights glucose monitoring products as the largest 2025 segment (34.8% share) and expects China to have the highest regional CAGR (11.1%).

Analysis

This reads more like TAM validation than a catalyst: the market is already assuming structural growth in decentralized diagnostics, so the investable edge is not the top-line CAGR but who captures recurring consumables, software/data workflows, and reimbursement-backed volume. That favors scaled platforms with installed bases and distribution depth — ABT, TMO, DHR, and to a lesser extent BDX — over smaller, single-category names whose growth can be offset by price erosion or lumpy test mix.

The second-order issue is channel power. If more testing migrates to home care and retail settings, margins will likely accrue to firms that own the user interface and the consumable pull-through, while pure reagent vendors face commoditization and local competition, especially in China where domestic champions can win on price and procurement. For U.S. multinationals, Asia growth is a revenue tailwind but not necessarily an earnings tailwind if mix shifts toward lower-ASP, higher-service geographies.

Time horizon matters: there is little day-one price reaction here, but over 1-3 months the real catalysts are earnings prints, glucose/CGM reimbursement commentary, and any evidence of share gains in decentralized testing. Over 6-18 months, the thesis is only confirmed if management teams translate TAM expansion into sustained gross margin and operating leverage; it is falsified by ASP compression, reimbursement setbacks, or slower-than-expected adoption in home testing. The market may be overpaying for the theme if it assumes all growth is durable rather than largely volume substitution from centralized labs.

Key Decisions for Investors

• Small starter long ABT vs. short QDEL, sized as a relative-value pair for 1-3 months: ABT has cleaner exposure to durable glucose/POC consumables and better scale economics; QDEL is more vulnerable to post-pandemic normalization and mix volatility. Falsify if QDEL reaccelerates recurring test volumes or ABT guides down consumable growth.
• Add TMO or DHR on weakness rather than chase the basket: these names monetize the broader diagnostic workflow and can absorb POC growth through distribution, instrumentation, and informatics. Risk/reward is better for 6-18 month compounding than for a near-term pop; stop if diagnostics segment growth decelerates versus the company average for two quarters.
• Avoid initiating fresh longs in smaller, category-specific names like OSUR or TRIB purely on this report; the growth theme is too diffuse and price competition can offset unit growth. Consider them only if upcoming earnings show gross margin stabilization and evidence of channel share gains.
• Set an alert on ABT/BDX/TMO earnings for glucose and home-testing commentary over the next 1-2 quarters; if management confirms double-digit growth in decentralized testing without margin pressure, add to winners. If reimbursement or ASP commentary weakens, reduce exposure quickly.